vasoprotective

{{Short description|Medication for conditions affecting blood vessels}}

A vasoprotective is a medication which acts to alleviate or prevent conditions or diseases which affect the blood vessels. The term is used in the World Health Organization's Anatomical Therapeutic Chemical Classification System to encompass therapeutic agents used in the treatment of hemorrhoids or varicose veins.{{Cite web|url=http://www.whocc.no/atc_ddd_index/?code=C05 |title=ATC/DDD Index |date=2019-12-16 |website=WHO Collaborating Centre for Drug Statistics Methodology |access-date=2020-01-28}} The term may also be used to describe drugs which lower the risk of developing hypercholesterolemia or hypertension.{{cite journal|author=Henry PD, Cabello OA |title=Vasoprotection and antihypertensive therapy. |journal=Curr Opin Nephrol Hypertens |year=1995 |volume=4 |issue=2 |pages=197–200 |pmid=7600051 |doi=10.1097/00041552-199503000-00014 }}

Examples of vasoprotectives include 1-methylnicotinamide,{{cite journal | pmid = 22353616 | year = 2012 | last1 = Domagala | first1 = T. B. | title = Nitric oxide production and endothelium-dependent vasorelaxation ameliorated by N¹-methylnicotinamide in human blood vessels | journal = Hypertension | volume = 59 | issue = 4 | pages = 825–832 | last2 = Szeffler | first2 = A. | last3 = Dobrucki | first3 = L. W. | last4 = Dropinski | first4 = J. | last5 = Polanski | first5 = S. | last6 = Leszczynska-Wiloch | first6 = M. | last7 = Kotula-Horowitz | first7 = K. | last8 = Wojciechowski | first8 = J. | last9 = Wojnowski | first9 = L. | last10 = Szczeklik | first10 = A. | last11 = Kalinowski | first11 = L. | doi = 10.1161/HYPERTENSIONAHA.111.183210 | s2cid = 302943 | doi-access = free }} estrogen,{{Cite journal|vauthors=Wassmann K, Wassmann S, Nickenig G |title=Progesterone antagonizes the vasoprotective effect of estrogen on antioxidant enzyme expression and function |journal=Circ. Res. |volume=97 |issue=10 |pages=1046–54 |date=November 2005 |pmid=16195479 |doi=10.1161/01.RES.0000188212.57180.55 |url=http://circres.ahajournals.org/cgi/pmidlookup?view=long&pmid=16195479|doi-access=free |url-access=subscription }} tribenoside,{{cite journal |author=Lorenc Z, Gökçe Ö |title=Tribenoside and lidocaine in the local treatment of hemorrhoids: an overview of clinical evidence. |journal=Eur Rev Med Pharmacol Sci |year=2016 |volume=20 |issue=12 |pages=2742–51 |pmid=27383331 |url=https://www.europeanreview.org/article/11037}} and valsartan.{{Cite journal|vauthors=Okumura M, Iwai M, Ide A, Mogi M, Ito M, Horiuchi M |title=Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression |journal=Hypertension |volume=46 |issue=3 |pages=577–83 |date=September 2005 |pmid=16103268 |doi=10.1161/01.HYP.0000178564.14464.80 |url=http://hyper.ahajournals.org/cgi/pmidlookup?view=long&pmid=16103268|doi-access=free }}

More specifically, arterial vasoprotectors are called angioprotectors.